Global Medical Device Leader Synthes Builds Production Base in SIP
The opening ceremony
On May 18, the opening ceremony of Synthes (Suzhou) Medical was held in Suzhou Industrial Park (SIP). The powerful production base of Synthes will enhance the upgrading of SIP cluster of over 180 biopharmaceutical enterprises, and contribute to the industrialization, scale expansion and further clustering of biopharmaceutical industry in SIP.
Yang Zhiping, Deputy Secretary of SIP CPC Working Committee & Director of SIP Administrative
Committee, attends the opening ceremony
Synthes is a leading global medical device company. As the single designated patented product manufacturer of AO/ASIF (Association for the Study of Osteosynthesis / Association for the Study of Internal Fixation), specializing in developing, producing and marketing instruments, implants and biomaterials for surgical fixation, correction and regeneration of the human skeleton and its soft tissues, Synthes ranks among the top three companies for spinal devices and is at the forefront of the cranio-maxillofacial business. To further expand Chinese market, Synthes planned to build production base in SIP at the end of Year 2008.
The workshop of Synthes (Suzhou) Medical
In recent years, taking new-emerging industries like biopharmacy as an important impetus for enhancing the independent innovative capability, SIP has become a significant sector of pharmaceutical industry in Suzhou. For promoting biopharmaceutical industry, SIP has set up 10 billion RMB industrial development fund, promulgated a series of policies and measures, as well as built industrial carriers like SIP Biobay.
Synthes (Suzhou) Medical Co., Ltd.
By now, over 180 biomedical enterprises have settled in SIP, including such Fortune 500 companies as GlaxoSmithKline and domestic enterprises like Suzhou Kaiyuan Minsheng Sci& Tech Co, which constitute a biological and pharmaceutical industry cluster covering the upstream, middle and down-stream of industrial chain. With over 10-billion-RMB output value, SIP has gradually become a cluster gathering biopharmaceutical core enterprises, core technologies and core talents.
May 19, 2010
